Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125269 | 0.94 | PLAU (0.50) | PLAUTPMTPOLBALOX15HTT | |
| SCHEMBL5024222 | 0.86 | ESR1 (0.38) | PLAUPOLBKDM4E | |
| SCHEMBL13125270 | 0.85 | PLAU (0.56) | PLAUTPMTPOLBALOX15HTT | |
| SCHEMBL13125212 | 0.81 | ESR1 (0.36) | PLAUPOLBHTT | |
| SCHEMBL13125271 | 0.78 | RXRA (0.47) | POLBKDM4EPLA2G2A | |
| SCHEMBL15968660 | 0.75 | HTT (0.56) | PLAUTPMTPOLBALOX15HTT | |
| SCHEMBL2376296 | 0.74 | MAPT (0.49) | HTTKDM4E | |
| SCHEMBL14804141 | 0.73 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL1665412 | 0.72 | RXRA (0.48) | POLBKDM4EPLA2G2A | |
| SCHEMBL5854524 | 0.71 | PLA2G4B (0.57) | POLBALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361658-B2 | 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl)piperidine-4-carboxylic acid; non-peptide thrombopoietin receptor (c-mpl-Ba/F3) ligand; less immunogenicity; platelet activator based on megakaryocyte colony; thrombocytopenia; orally | ASTELLAS PHARMA INC. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647553-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, MATK | PLAU 2807/4885TPMT 1614/4885POLB 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.